New drug testing for relapsed Ewing sarcoma
Part of Cancer clinical trials.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 years old or older.
- You must have Ewing sarcoma, desmoplastic small round cell tumor, or soft tissue sarcoma that has returned or not responded to treatment.
- You must have already received at least two different chemotherapy regimens.
- You must have at least one measurable tumor on scans.
- You must be in good general health (able to perform daily activities).
- You must not have severe heart, lung, kidney, liver, or nervous system problems, or a history of certain heart rhythm issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
This study is testing whether a blood test called ProGRP can help doctors see how well treatment is working in people with Ewing sarcoma. If you are newly diagnosed and are about to start your first treatment, this study may help improve how we track your progress.
This trial tests a new immunotherapy that targets a specific genetic change found in Ewing sarcoma and DSRCT tumors. It may help people whose cancer has come back or is hard to treat.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.